Synthesis and Development of Novel Radiopharmaceuticals for Targeted Radiotherapy and Theranostics
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".
Deadline for manuscript submissions: 22 September 2024 | Viewed by 578
Special Issue Editor
Special Issue Information
Dear Colleagues,
Tumors are pathological complexes composed of cancerous and non-cancerous cells that communicate through networks regulated by acellular factors such as cytokines, inflammatory enzymes, chemokines, growth factors, and extracellular matrix components. Investigating the critical role of cells and proteins associated with the tumor microenvironment and cancer cells is a priority objective in the field of cancer biology. However, cancer proteomics has shown that the expression of specific molecular targets is dynamic, which has transformed nuclear molecular imaging techniques from purely diagnostic to disease prognostic procedures for accurate treatment selection. More specifically, current developments in radiopharmaceuticals for targeted radiotherapy and theranostics are aimed at innovating new radioligands with specific molecular targeting and selective radioactivity delivery to cancer cells and the tumor microenvironment. For example, the 177Lu- and 225Ac-based radiopharmaceuticals targeting the PSMA protein and somatostatin receptors, along with their diagnostic radionuclide pairs (theranostic pairs), are experiencing exponential growth worldwide as nuclear molecular imaging and targeted radiotherapy agents for prostate cancer and tumors of neuroendocrine origin.
Pharmaceuticals invites both reviews and original articles that highlight recent innovations in the development of molecularly targeted radiopharmaceuticals. Topics include the synthesis and chemical characterization of new radioligands with molecular targeting to cancer cells or the tumor microenvironment (diagnostic and/or therapeutic applications), production methods of new radionuclides with optimal properties for targeted radiotherapy or as theranostic pairs, radio-nanopharmaceuticals (radio-nanoparticles) useful in targeted radiotherapy or theranosticso, dosimetric aspects in the application of molecularly targeted radiopharmaceuticals, preclinical and clinical studies of new radiopharmaceuticals for targeted radiotherapy or as potential theranostic pairs. The collection of manuscripts will be published in a Special Issue of the journal.
Dr. Guillermina Ferro-Flores
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiopharmaceuticals
- targeted radiotherapy
- internal dosimetry
- radionuclide production
- nuclear molecular imaging
